By Kyle LaHucik
Pfizer and Novartis' venture arms have joined investment firms in backing a $119 million series B for Anaveon. The Swiss biotech will deploy the proceeds on a phase 1/2 study in solid tumors.
read more
By Paige Minemyer
UnitedHealth and Change are awaiting the completion of an investigation into the merger by the Department of Justice, which has been probing the deal on antitrust grounds.
read more
By Conor Hale
The company has latched onto the recent craze for trading non-fungible tokens, raising $4.2 million from sales of images that were algorithmically created using patterns driven by its deep learning platform.
read more
By Ben Adams
Biogen is looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s disease drug Aduhelm out in four years, as the fate of this drug, and Biogen itself, rests in the balance.
read more
By Kyle LaHucik
Horizon Therapeutics will dole out up to $1.5 billion in milestone payments to bring up to four Alpine drugs from the horizon all the way to the top of the Alps.
read more
By Heather Landi
The financial and workplace pressures brought on by the COVID-19 pandemic are putting a major strain on physicians, impacting their pay as well as job satisfaction, according to a new survey. Doximity reports average compensation is essentially down due to inflation. Here's a look at which specialties are still seeing the most growth in 2021.
read more
By Andrea Park
Forget finnicky blood draws and painful finger pricks—now, blood samples can be collected with the push of a button.
read more
By Angus Liu
Newly unveiled data will likely establish CAR-T therapies as the new standard of care in certain second-line patients with aggressive B-cell lymphoma. For Gilead Sciences’ Yescarta, that indication could mean $1.5 billion in sales over time, analysts at RBC Capital Markets said.
read more
By Annalee Armstrong
It’s the battle of the boosters. A day after Sanofi and GlaxoSmithKline said their COVID-19 shot works well as a booster for other shot regimens, Valneva and Arcturus Therapeutics are adding to the chorus.
read more
By Paige Minemyer
U.S. healthcare spending skyrocketed in 2020 as the federal government invested significantly in response to the COVID-19 pandemic, according to new data from CMS.
read more